**7. References**


Clinical proof of concept for polymer conjugates has already been achieved over the last three decades, with a family of polymer-protein conjugates reaching the market and a growing list of polymer-drug conjugates currently in clinical studies. The application of polymer-anticancer drug conjugates in anticancer treatment is a promising field with growing opportunities to achieve medical treatments with highly improved therapeutic value (Vicent et al., 2008). PG-PTX conjugate can improve the anticancer activity, enhance the safety and efficacy, ameliorate the pharmacokinetic properties and so on. Therefore, the

However, many challenges still exist, providing opportunities to improve this platform technology further. The clinical development of anticancer agents utilizing various delivery systems is actively undergoing. New technologies and multidisciplinary approaches to develop advanced drug delivery systems, applicable to a wide range of anticancer agents,

This work was supported by the National Key Technologies R & D Program for Drug Safety Evaluation (Grant No. 2008ZX09305-002) and the Scientific Research Foundation for the

Bhalla, K. N. (2003). Microtubule-targeted anticancer agents and apoptosis. *Oncogene*, Vol.

Boddy, A. V.; Griffin M. J.; Sludden J.; Thomas H. D.; Fishwick K.; Wright J. G.; Plumner E.

Boddy, A. V.; Plummer E. R.; Todd R.; Sludden J.; Griffin M.; Robson L.; Cassidy J.; Bissett

Bonomi, P. (2007). Paclitaxel poliglumex (PPX, CT-2103): macromolecular medicine for

Chipman, S. D.; Oldham F. B.; Pezzoni G. & Singer J. W. (2006). Biological and clinical

Greco, F. & Vicent M. J. (2008). Polymer-drug conjugates: current status and future trends. *Frontiers in Bioscience*, Vol. 13, No., 2008), pp. 2744-2756, ISSN 1093-4715

R.; Highley M. & Calvert A. H. (2001). Pharmacological study of paclitaxel duration of infusion combined with GFR-based carboplatin in the treatment of ovarian cancer. *Cancer chemotherapy and pharmacology*, Vol. 48, No. 1, (July 2001), pp. 15-21,

D.; Bernareggi A.; Verrill M. W. and others. (2005). A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2 weekly schedules. *Clinical Cancer Research*, Vol. 11, No. 21, (November 2005), pp.

advanced non-small-cell lung cancer. *Expert Review of Anticancer Therapy*, Vol. 7,

characterization of paclitaxel poliglumex (PPX, CT-2103), a macromolecular polymer-drug conjugate. *International Journal of Nanomedicine*, Vol. 1, No. 4, 2006),

22, No. 56, (December 2003), pp. 9075-9086, ISSN 0950-9232

application of PG-PTX facilitates the clinical therapy of a variety of human cancers.

may eventually lead to an effective cancer therapy in the future.

Returned Overseas Chinese Scholars, State Education Ministry.

No. 4, (April 2007), pp. 415-422, ISSN 1744-8328

**5. Summary** 

**6. Acknowledgement** 

ISSN 0344-5704

7834-7840, ISSN 1078-0432

pp. 375-383, ISSN 1176-9114

**7. References** 


xenografted tumors. *Clinical Cancer Research*, Vol. 5, No. 4, (April 1999), pp. 891-897, ISSN 1078-0432


Li, C.; Yu D.; Inoue T.; Yang D. J.; Milas L.; Hunter N. R.; Kim E. E. & Wallace S. (1996).

Li, C.; Yu D. F.; Newman R. A.; Cabral F.; Stephens L. C.; Hunter N.; Milas L. & Wallace S.

Li, C.; Yu D. F.; Newman R. A.; Cabral F.; Stephens L. C.; Hunter N.; Milas L. & Wallace S.

Luo, Y. & Prestwich G. D. (2002). Cancer-targeted polymeric drugs. *Current Cancer Drug Targets*, Vol. 2, No. 3, (September 2002), pp. 209-226, ISSN 1568-0096 Maeda, H.; Bharate G. Y. & Daruwalla J. (2009). Polymeric drugs for efficient tumor-targeted

*Biopharmaceutics:*, Vol. 71, No. 3, (March 2009), pp. 409-419, ISSN 1873-3441 Maeda, H.; Wu J.; Sawa T.; Matsumura Y. & Hori K. (2000). Tumor vascular permeability

Milas, L.; Mason K. A.; Hunter N.; Li C. & Wallace S. (2003). Poly(L-glutamic acid)-paclitaxel

Mita, M.; Mita A.; Sarantopoulos J.; Takimoto C. H.; Rowinsky E. K.; Romero O.; Angiuli P.;

Multani, A. S.; Li C.; Ozen M.; Imam A. S.; Wallace S. & Pathak S. (1999). Cell-killing by

Oldham, E. A.; Li C.; Ke S.; Wallace S. & Huang P. (2000). Comparison of action of paclitaxel

Parveen, S. & Sahoo S. K. (2008). Polymeric nanoparticles for cancer therapy. *Journal of drug targeting*, Vol. 16, No. 2, (February 2008), pp. 108-123, ISSN 1061-186X Podgorski, I. & Sloane B. F. (2003). Cathepsin B and its role(s) in cancer progression. *Biochemical Society Symposium*, Vol. No. 70, 2003), pp. 263-276, ISSN 0067-8694

No. 1, (January-February 1999), pp. 39-44, ISSN 1021-335X

*Release*, Vol. 65, No. 1-2, (March 2000), pp. 271-284, ISSN 0168-3659

ISSN 1078-0432

ISSN 0959-4973

0360-3016

1432-0843

1019-6439

1998a), pp. 2404-2409, ISSN 0008-5472

(June 1998b), pp. 2404-2409, ISSN 0008-5472

xenografted tumors. *Clinical Cancer Research*, Vol. 5, No. 4, (April 1999), pp. 891-897,

Synthesis and evaluation of water-soluble polyethylene glycol-paclitaxel conjugate as a paclitaxel prodrug. *Anticancer Drugs*, Vol. 7, No. 6, (August 1996), pp. 642-648,

(1998a). Complete regression of well-established tumors using a novel watersoluble poly(L-glutamic acid)-paclitaxel conjugate. *Cancer Res*, Vol. 58, No. 11, (Jun

(1998b). Complete regression of well-established tumors using a novel watersoluble poly(L-glutamic acid)-paclitaxel conjugate. *Cancer Research*, Vol. 58, No. 11,

drug delivery based on EPR-effect. *European Journal of Pharmaceutics and* 

and the EPR effect in macromolecular therapeutics: a review. *Journal of Controlled* 

conjugate is a potent enhancer of tumor radiocurability. *International Journal of Radiation Oncology, Biology, Physics*, Vol. 55, No. 3, (March 2003), pp. 707-712, ISSN

Allievi C.; Eisenfeld A. & Verschraegen C. F. (2009). Phase I study of paclitaxel poliglumex administered weekly for patients with advanced solid malignancies. *Cancer chemotherapy and pharmacology*, Vol. 64, No. 2, (July 2009), pp. 287-295, ISSN

paclitaxel in a metastatic murine melanoma cell line is mediated by extensive telomere erosion with no decrease in telomerase activity. *Oncology Reports*, Vol. 6,

and poly(L-glutamic acid)-paclitaxel conjugate in human breast cancer cells. *International Journal of Oncology*, Vol. 16, No. 1, (January 2000), pp. 125-132, ISSN


*chemotherapy and pharmacology*, Vol. 63, No. 5, (April 2009), pp. 903-910, ISSN 1432- 0843

Vicent, M. J.; Dieudonne L.; Carbajo R. J. & Pineda-Lucena A. (2008). Polymer conjugates as therapeutics: future trends, challenges and opportunities. *Expert Opinion on Drug Delivery*, Vol. 5, No. 5, (May 2008), pp. 593-614, ISSN 1742-5247
